Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment.

Open Forum Infect Dis · 2025 · PMC12575079 · PMID 41180000

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

There was also a nonsignificant trend suggesting a higher probability of DTG/3TC initiation in individuals with dyslipidemia or hypertension.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.